Key Principles and Recommended Regimens for First-line Antiretroviral Therapy

  • Author: Paul E. Sax, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/5/18 (What's New)

Summary

  • The phase III DRIVE-AHEAD trial compared doravirine with efavirenz in treatment-naive adults[Orkin 2018]
    • Doravirine was found to be noninferior to efavirenz, with consistent virologic suppression rates (HIV-1 RNA < 50 copies/mL) across most patient subgroups with the exception of those defined by age
  • Based on results of DRIVE-AHEAD and the phase III DRIVE-FORWARD trial, the FDA approved doravirine for treatment-naive adults, both as a single agent to be used in combination with other ARVs and as a once-daily, single-tablet regimen coformulated with lamivudine and tenofovir DF[FDA Doravirine; FDA DOR/3TC/TDF]

Action required